Page 6,507«..1020..6,5066,5076,5086,509..6,5206,530..»

Could this stem cell cure for wrinkles end the endless hunt for the perfect skin cream?

Posted: Published on September 10th, 2012

British firm is trialling new method by injecting patient's own stem cells to restore skin's youthful elasticity By Tamara Cohen PUBLISHED: 10:40 EST, 9 September 2012 | UPDATED: 02:12 EST, 10 September 2012 Scientists will begin clinical trials in 12 months, using stem cells harvested from a blood sample from the patients Scientists are working on a new weapon in the war against wrinkles. There are not many things women have not tried in the quest for a youthful complexion from lotions and potions to Botox and cosmetic surgery. But a British firm is trialling a new method which involves injecting the patients own stem cells to restore skins youthful elasticity. Researchers believe they will spur the growth of new skin cells, called fibroblasts, which make the elastic ingredient collagen which is produced in large quantities when we are young, but declines as we age. The company Pharmacells, based in Glasgow, plan to begin clinical trials in 12 months, using stem cells harvested from a blood sample from the patients. They believe the procedure could be commercially available in just three years, potentially revolutionising the market for anti-ageing treatments. Read more here: Could this stem cell cure for wrinkles end … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Could this stem cell cure for wrinkles end the endless hunt for the perfect skin cream?

Researchers reveal a chemo-resistant cancer stem cell as cancer's 'Achilles' heel'

Posted: Published on September 10th, 2012

Public release date: 10-Sep-2012 [ | E-mail | Share ] Contact: Mount Sinai Press Office newsmedia@mssm.edu 212-241-9200 The Mount Sinai Hospital / Mount Sinai School of Medicine Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell. Resistance to chemotherapy is a frequent and devastating phenomenon that occurs in cancer patients during certain treatments. Unfortunately, tumors that initially respond to chemotherapy eventually become resistant to it, contributing to tumor progression and death. The study reveals that these new cancer "stem" cells, which have not been differentiated into more specific cell types, are capable of multiplying despite being exposed to chemotherapy, while differentiated cells die. Led by Carlos Cordon-Cardo, MD, PhD, Chair of Pathology, and Josep Domingo-Domenech, MD, PhD, Assistant Professor of Pathology at Mount Sinai, the research team generated cellular models of drug resistance by treating prostate tumor cell lines with increasing doses of the common chemotherapy drugs, including docetaxel. They identified a cell population expressing markers … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Researchers reveal a chemo-resistant cancer stem cell as cancer's 'Achilles' heel'

Chemotherapy-resistant cancer stem cell could be 'Achilles' heel' of cancer

Posted: Published on September 10th, 2012

ScienceDaily (Sep. 10, 2012) Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell. Resistance to chemotherapy is a frequent and devastating phenomenon that occurs in cancer patients during certain treatments. Unfortunately, tumors that initially respond to chemotherapy eventually become resistant to it, contributing to tumor progression and death. The study reveals that these new cancer "stem" cells, which have not been differentiated into more specific cell types, are capable of multiplying despite being exposed to chemotherapy, while differentiated cells die. Led by Carlos Cordon-Cardo, MD, PhD, Chair of Pathology, and Josep Domingo-Domenech, MD, PhD, Assistant Professor of Pathology at Mount Sinai, the research team generated cellular models of drug resistance by treating prostate tumor cell lines with increasing doses of the common chemotherapy drugs, including docetaxel. They identified a cell population expressing markers of embryonic development. In addition, these cells displayed cancer stem cell functions, including the capacity to initiate tumor cell growth. Next, the team … Continue reading

Comments Off on Chemotherapy-resistant cancer stem cell could be 'Achilles' heel' of cancer

Hero dog gets stem cell treatment

Posted: Published on September 10th, 2012

By Julie S. Alipala Inquirer Mindanao ZAMBOANGA CITYKabang, the female Aspin dog who lost her upper snout when hit by a motorcycle while saving the lives of two girls, will be staying in Manila for two weeks for a stem cell treatment before further surgery in the United States. Veterinarian Anton Lim said the stem cell treatment will boost the dogs immunity before she is flown to the US within the month. Kabang was flown to Manila on Sunday morning. Lim said they were able to raise at least $10,000 from donations to shoulder expenses for Kabangs surgery on a protruding bone on her face. We are halfway there. As I have said, we need around $20,000, he said. Team Kabang is really grateful for the global effort as we received donations from almost a dozen countries, he added. The Animal Welfare Coalition of the Philippines has also helped provide medicines for Kabang. Follow Us Recent Stories: Tags: Animal Welfare Coalition of the Philippines , Aspin dog , Kabang , stem cell treatment , surgery Factual errors? Contact the Philippine Daily Inquirer's day desk. Believe this article violates journalistic ethics? Contact the Inquirer's Reader's Advocate. Or write The Readers' Advocate: … Continue reading

Comments Off on Hero dog gets stem cell treatment

DART Therapeutics Appoints Executive Team

Posted: Published on September 10th, 2012

CAMBRIDGE, Mass., Sept. 10, 2012 /PRNewswire/ --DART Therapeutics, LLC, an innovative, new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), announced today the appointment of its executive team. Co-Founder and Executive Chairman Eugene W. Williams transitions to a full-time role as CEO, and Ernest D. Bush Ph.D. joins as Chief Scientific Officer. DART also adds Dr. Elliot Goldstein as Chief Medical Officer and Cabot Brown as Chief Financial Officer, both on a part-time basis. Each will apply more than 25 years of executive-level experience in his respective field to expedite development of a therapy for DMD. DART was co-founded in 2010 by two leading patient foundations in DMD, Charley's Fund and the Nash Avery Foundation, along with Executive Chairman Gene Williams. It has derived funding to date exclusively from these foundations. As a patient-funded biotechnology firm, DART reflects a new model for research and drug development centered on the needs of families affected by DMD and potentially transportable to other pediatric rare diseases. While DART is patient-funded and founded, it benefits from professional staff and business processes like any other well-managed biotech. In its first two years, DART acquired a promising clinical stage anti-fibrotic drug candidate and … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on DART Therapeutics Appoints Executive Team

Supplement May Treat Autism In Some

Posted: Published on September 10th, 2012

}{s@nMQzio3iG"Yt~OrwKeN3bX,Ox{~K6&.~9sn7_?~Z&EcEyj( Ls65fw=Bia5}iH#Pd9x&1#3|5F z>6w,MT&&>X,0C!lGG44zIsg5*"]`,- Oc+HC~ w0 *@9abM#V CvLyh;!T"1v]?K,j6aZ6MeTa ?Oyu {:qxq-3?0%~_q,5'P+"F3G{|LFjMH1h| {G((]@5a0Ri;wW%tQyw zk3w632ZljVe .]a@K{`G{dST?%m)n~8Tuljp7a|og*1unA"p&8.##|vZLW3YVMqi +v{k3Ka(/{/fou1%=w 7Cw S-73!s^!CoE|FR)V9 sX^1{,iExV(P]RP">b3KeBMSTE=-DsVyNFG;t TbchQ *5B[1(*p~(_/'4jJ' tT{z{;K.{O&T+v*.|6"||4jv?COY#GOSo@FWKC&zi'(tzhU8TjkTh+_m?BW7VU+Z"0D. Ys@e0ez-TP9q1=QV,.T=r7Z*F`-R'0V!jPH /W>kvOX1~!p" U([YXaFkl@8p2yU'/=[u1{B0qgy,!IL[fMul jciaNQo"&yC+]0I">lM.fsK)UTQ4ZWSX CBJ%%dE2|HKjtBJ23%T7U8X 5s'g.%iFnmLh.U&=("$smWXyuKrF+V`V=gMO@lmZEt"RFU[@,Amg".~{^D]G^"^JsP*Pgs&}"FFYEPQq*jFBPR&yr CNxxO{3X@vLj7i*vY[$%k~^fu :+XjMgo]=8? nc2 (*-|Lzp$;M/kTvVeyhD+rFs3^&1rsA-{]1/I;}YI2cq| … Continue reading

Comments Off on Supplement May Treat Autism In Some

Florida Hospital Tampa First to Adopt New Stroke Retrieval Device

Posted: Published on September 10th, 2012

TAMPA, Fla.--(BUSINESS WIRE)-- Florida Hospital Tampa and Dr. James E. Lefler are the first in the Tampa Bay area to adopt the new FDA approved device called the Trevo Pro Clot Retriever manufactured by Stryker. The Trevo Pro is the next generation in clot removal technology. This powerful new tool literally retrieves blood clots from within the brains vasculature restoring blood flow to the brain faster for patients suffering from acute ischemic stroke, where blood flow is blocked. This new device has the ability to significantly improve patient outcomes. Trevo Pro is used to perform what is called a mechanical thrombectomy, also known as clot removal, said James E. Lefler, MD, co-director of the stroke program and neurointerventional radiologist at Florida Hospital Tampa. The Trevo Pro entraps the clot in a way that can immediately allow blood to start flowing back to the brain. This new device is 92% effective, advancing our ability and leading patients to better outcomes. We now have four different devices to treat stroke patients, depending on the type and location of stroke. The Trevo Pro becomes a fourth option; our other devices include the Concentric Merci Retrieval System, The Penumbra System and Solitaire Stroke Device. … Continue reading

Comments Off on Florida Hospital Tampa First to Adopt New Stroke Retrieval Device

Parkinson's Brain Chemistry Changes Now Trackable in Man

Posted: Published on September 10th, 2012

EMERYVILLE, Calif.--(BUSINESS WIRE)-- KineMed, Inc. (www.kinemed.com) announced today the publication of a novel discovery in biomarkers for neurodegenerative diseases from a study funded by The Michael J. Fox Foundation. The absence of meaningful biomarkers has remained a roadblock in the development and clinical application of treatments for neurological disorders. The publication describes in detail a unique class of biomarkers that measure the transport efficiency of key cargo molecules through neurons in the living human brain. Biomarkers of this pathogenically causal process may be used for the development of drugs to treat Parkinsons disease. The study published in the current edition of the Journal of Clinical Investigation (J Clin Invest. doi: 10.1172/JCI64575 http://www.ncbi.nlm.nih.gov/pubmed/22922254) extends the use of KineMeds proprietary heavy water (2H2O)/protein dynamics mass spectrometric platform that provides real-time measurements of the flow of molecules through specific biochemical pathways in vivo. Researchers, led by Dr. Patrizia Fanara at KineMed, Inc., and Dr. Marc Hellerstein at the University of California, Berkeley and KineMed, Inc., working with collaborators at the University of California San Francisco and the University of Osnabruck, Germany, used the 2H2O labeling approach to specifically track, for the first time, the movement of cargo proteins that rely on axonal transport … Continue reading

Posted in Parkinson's Treatment | Comments Off on Parkinson's Brain Chemistry Changes Now Trackable in Man

Dr. Randall Benson to Present at Conference on Legal Issues in Brain Injury

Posted: Published on September 10th, 2012

Novi, MI (PRWEB) September 10, 2012 Dr. Randall Benson will present on the latest techniques in neuroimaging at the North American Brain Injury Societys (NABISs) 25th Annual Conference on Legal Issues in Brain Injury, September 13-15, in Miami, FL. Dr. Benson is nationally recognized for his research into traumatic brain injury (TBI). In 2010, Benson testified before the U.S. Congress Judiciary Committee on his research into neuroimaging of retired National Football League (NFL) players. Earlier this week, the NFL announced it had granted $30 million to the National Institutes of Health for medical research. The announcement followed research that suggests NFL players are at higher risk of death from brain disorder than the general population. Dr. Benson holds a dual fellowship in behavioral neurology and functional neuroimaging from Massachusetts General Hospital. He received his residency training in neurology at the Boston University School of Medicine. A board-certified neurologist and medical director at the Center for Neurological Studies (CNS), he has authored or co-authored numerous research articles in juried publications, has spoken on the topic of brain injury/disorder around the world, and has been and is involved in significant research projects. At the NABIS conference, Dr. Bensons presentation will focus on … Continue reading

Posted in Brain Injury Treatment | Comments Off on Dr. Randall Benson to Present at Conference on Legal Issues in Brain Injury

Opexa to Participate at Upcoming Industry Conferences

Posted: Published on September 10th, 2012

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (OPXA), a company developing Tcelna, a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil Warma, President and Chief Executive Officer, will participate in two upcoming industry conferences. Details regarding these events are as follows: Intellectual Property Owners Association (IPO) Annual Meeting This conference will take place September 9-11, 2012 at the JW Marriott Hill Country in San Antonio, Texas. Each year, the organizers of the IPO Annual Meeting invite one CEO to deliver a keynote luncheon address. This year, Mr. Warma has been selected to provide insight on the role of intellectual property rights from the perspective of business. The 8thAnnual Burrill Personalized Medicine Meeting This meeting of researchers, drug developers, analysts, investors and other life science industry representatives will take place September 13-14, 2012 at the Bentley Reserve & Conference Center in San Francisco. Mr. Warma will join several additional panelists as they discuss the implications that advances in personalized medicine are having on the drug development business. Mr. Warma will share Opexas experiences regarding the clinical development of Tcelna, the first ever personalized T-cell therapy for MS patients. About Opexa Opexa Therapeutics, Inc. is dedicated to the development … Continue reading

Posted in MS Treatment | Comments Off on Opexa to Participate at Upcoming Industry Conferences

Page 6,507«..1020..6,5066,5076,5086,509..6,5206,530..»